Evidence map›Paper›PMID 31249137›Full record

ArticleThe oncologist2019

Samuel J Klempner, Russell Madison, Vivek Pujara, Jeffrey S Ross, Vincent A Miller, Siraj M Ali, Alexa B Schrock, Seung Tae Kim, Steven B Maron, Farshid Dayyani and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. FGFR2 amplification and fusion identified by NGS align with FGFR2b overexpression.Virchows Archiv : an international journal of pathology · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 2 countries.

Samuel J KlempnerThe Angeles Clinic and Research Institute, Los Angeles California, USA sklempner@theangelesclinic.org.ORCID 0000-0002-4062-0808
Russell MadisonFoundation Medicine, Inc., Cambridge, Massachusetts, USA.
Vivek PujaraThe Angeles Clinic and Research Institute, Los Angeles California, USA.
Jeffrey S RossFoundation Medicine, Inc., Cambridge, Massachusetts, USA.
Vincent A MillerFoundation Medicine, Inc., Cambridge, Massachusetts, USA.
Siraj M AliFoundation Medicine, Inc., Cambridge, Massachusetts, USA.
Alexa B SchrockFoundation Medicine, Inc., Cambridge, Massachusetts, USA.ORCID 0000-0003-0106-9096
Seung Tae KimSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Steven B MaronDivision of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-8794-130X
Farshid DayyaniDivision of Hematology-Oncology, Department of Medicine, University of California Irvine, Orange, California, USA.ORCID 0000-0002-4970-5189
Daniel V T CatenacciDepartment of Medicine, Division of Hematology-Oncology, University of Chicago School of Medicine, Chicago, Illinois, USA.ORCID 0000-0001-7517-8020
Jeeyun LeeSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Joseph ChaoDepartment of Developmental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA.ORCID 0000-0002-1809-504X
Foundation Medicine (United States)Angeles Clinic and Research Institute · USCity of Hope · USMemorial Sloan Kettering Cancer Center · USSamsung Medical Center · KRSungkyunkwan University · KRSUNY Upstate Medical University · USUniversity of California, Irvine · USUniversity of Chicago · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI MARK W. LINGEN · 1985 to 2026
$122.1M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014599
6 · The paper itself

Abstract

backgroundWith the exception of trastuzumab, therapies directed at receptor tyrosine kinases (RTKs) in gastroesophageal adenocarcinomas (GEA) have had limited success. Recurrent fibroblast growth factor receptor 2 (FGFR2) alterations exist in GEA; however, little is known about the genomic landscape of SUBJECTS, MATERIALS, AND

methodsA total of 6,667 tissue specimens from patients with advanced GEA were assayed using hybrid capture-based genomic profiling. Tumor mutational burden (TMB) was determined on up to 1.1 Mb of sequenced DNA, and microsatellite instability was determined on 95 or 114 loci. Descriptive statistics were used to compare subgroups.

resultsWe identified a total of 269 (4.0%)

conclusionIMPLICATIONS FOR PRACTICE: Actionable receptor tyrosine kinase alterations assayed within a genomic context with therapeutic implications remain limited to

Indexed as

Gene Expression Regulation, NeoplasticAdenocarcinomaBiomarkers, TumorEsophageal NeoplasmsEsophagogastric JunctionFemaleFollow-Up StudiesHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationPrognosisReceptor, Fibroblast Growth Factor, Type 2Retrospective StudiesStomach NeoplasmsBiomarkers, TumorFGFR2 protein, humanReceptor, Fibroblast Growth Factor, Type 2Fibroblast growth factor receptor 2Gastric cancerGastroesophageal junction adenocarcinomaHeterogeneityReceptor tyrosine kinase

Identifiers

PMID31249137
PMCPMC6853122
OpenAlexW2954826640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.